Driving Precision Medicine and Clinical Success
Biomarkers play a pivotal role in drug development by validating hypotheses, translating therapies into clinical practice, and monitoring treatment effects in trials. Despite being a time-intensive process, identifying effective biomarkers early in preclinical research is essential for guiding drug development and improving patient outcomes.
For biomarkers to be clinically valuable, they must be directly linked to the disease mechanism or drug activity and be measurable in accessible biological samples, such as blood or other body fluids. This is where CETSA® offers a distinct advantage.
Through unbiased, proteome-wide profiling, CETSA enables the discovery of previously unknown biomarkers associated with drug response while also helping to map the biological pathways affected by treatment. This approach refines biomarker selection and validation, ensuring the identification of relevant markers that can predict patient response and support precision medicine strategies.
Additionally, CETSA can be applied directly to patient-derived materials, ensuring that biomarkers remain clinically relevant throughout the drug development process. Integrating CETSA into your biomarker discovery efforts can improve clinical success rates, optimize treatment strategies, and contribute to better patient survival outcomes.
Key Benefits
- Unbiased Biomarker Discovery – Identify novel biomarkers linked to drug response through comprehensive proteome-wide profiling.
- Enhanced Precision Medicine Support – Discover biomarkers that help predict patient response and guide personalized treatment strategies.
- Clinically Relevant Validation – Ensure biomarkers are applicable by testing in patient-derived materials throughout development.
How It Works
Our biomarker discovery service leverages the power of CETSA technology to streamline the identification and validation of meaningful biomarkers:
- Proteome-Wide Profiling – Unbiased screening of protein interactions and pathway changes associated with drug treatment.
- Biomarker Identification and Selection – Discover and prioritize biomarkers based on their relevance to the disease mechanism and treatment response.
- Clinical Validation – Confirm biomarker relevance using patient-derived material to ensure applicability in clinical development.
Ready to accelerate your biomarker discovery efforts?
Contact Pelago Bioscience today to learn how our CETSA-powered services can help drive precision medicine and improve clinical outcomes.
Get in touch
Contact us to learn more, to book a meeting or request a quote.